PharmacoEconomics & Outcomes News 792, p4 - 2 Dec 2017 Treatments for TD: limited evidence, high cost The evidence of the clinical benefit and long-term safety of valbenazine and deutetrabenazine for the treatment of tardive dyskinesia (TD) is uncertain, and these agents are not cost effective at current wholesale acquisition cost (WAC). These are the main findings of an evidence report, released by the Institute for Clinical and Economic Review (ICER), which assessed the comparative clinical effectiveness and value of valbenazine [Ingrezza], deutetrabenazine [Austedo] and tetrabenazine [Xenazine] for management of TD. For valbenazine and deutetrabenazine, the report found inconclusive evidence for the treatment of TD, mainly due to uncertainty surrounding key outcome measures studied in clinical trials, as well as a lack of long-term safety data. For tetrabenazine, the evidence was insufficient to assess its net health benefit. Economic analyses showed that both valbenazine and deutetrabenazine were not cost effective at $US752 000 and $1.1 million per QALY, respectively. The analyses also showed that the annual WAC of valbenazine (currently $76 000) would need to fall to $7600–$11 260, a discount of 85%–90%, to align the cost with the benefit provided to patients. Similarly, the annual WAC of deutetrabenazine (currently $90 000) would need to fall to $6200–$9200, a discount of 90%–93%. Tetrabenazine was not included in these economic analyses due to data limitations. ICER. Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patients. Internet Document : 21 Nov 2017. Available from: URL: https://icer-review.org/announcements/tardive-dyskinesia-evidence-report/ 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera